Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges - Top-Institutions - MDSpire

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • By

  • Sirajunisa Talath

  • Mohamed El-Tanani

  • Adil Farooq Wali

  • Syed Arman Rabbani

  • Bhoomendra Bhongande

  • Walaa Ibraheem

  • Ashot Avagimyan

  • Karolina Hoffmann

  • Ioannis Ilias

  • Sorina Ispas

  • Maggio Viviana

  • Anna Paczkowska

  • Manfredi Rizzo

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Oncology
    • Integrative Medicine
    • Pharmacology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Cancer Research
    • Integrative Medicine
    • Clinical Pharmacology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology
    • Complementary and Integrative Therapies
    • Translational Research

  • #4

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Breast Cancer
    • Integrative Oncology
    • Pharmacology

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Breast Cancer
    • Integrative Medicine
    • Pharmacology

Original Source(s)

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • by Sirajunisa Talath, Mohamed El-Tanani, Adil Farooq Wali, Syed Arman Rabbani, Bhoomendra Bhongande, Walaa Ibraheem, Ashot Avagimyan, Karolina Hoffmann, Ioannis Ilias, Sorina Ispas, Maggio Viviana, Anna Paczkowska, Manfredi Rizzo

  • April 30, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate